title: Allogeneic bone marrow transplantation in children with acute myelogenous leukemia in first remission. Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO).
abstract: Fifty-nine children, aged 1-15 years, with acute myelogenous leukemia (AML) received a bone marrow transplant (BMT) from an HLA-identical sibling (n = 57) or from an identical twin (n = 2), while in first remission (CR). These children represent, to the best of our knowledge, all children grafted in first CR in 11 Italian centers between 1980 and 1990. Patients were prepared with total body irradiation (TBI) plus cyclophosphamide (CY) (n = 50) or melphalan (n = 2) or with busulfan plus CY (n = 7). GVHD prophylaxis consisted of cyclosporin A (n = 48), methotrexate (n = 7) or cyclosporin and methotrexate (n = 2). Survivors have been followed for 21-137 months (median 59 months). Actuarial relapse-free survival was 58% at 66-137 months (95% confidence interval (CI) 44-72). Actuarial risk of relapse was 23% at 48 months (95% CI 10.9-34.8). Risk of non-relapse deaths was 33% in the period 1980-87 and 4% in the period 1988-90 (p = 0.02). In multivariate analysis patients with a blood cell count > 14 x 10(9)/l at diagnosis showed a lower relapse-free survival compared with patients with counts < 14 x 10(9)/l (p = 0.006). We could not detect an effect of FAB subtype, patient age, time to achieve remission or transplant-related variables, including year of BMT, on relapse-free survival. In conclusion, allogeneic marrow transplantation can achieve long-term relapse-free survival in over 50% of children with AML and should be considered as consolidation therapy if a matched sibling is available.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pediatric Hematology/Oncology-Bone Marrow Transplant Unit, Istituto Giannina Gaslini, Genova, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Dini
authors.forename: L
authors.initials: L
authors.lastname: Boni
authors.forename: O
authors.initials: O
authors.lastname: Abla
authors.forename: C
authors.initials: C
authors.lastname: Uderzo
authors.forename: P
authors.initials: P
authors.lastname: Polchi
authors.forename: F
authors.initials: F
authors.lastname: Locatelli
authors.forename: P
authors.initials: P
authors.lastname: Di Bartolomeo
authors.forename: W
authors.initials: W
authors.lastname: Arcese
authors.forename: A P
authors.initials: AP
authors.lastname: Iori
authors.forename: F
authors.initials: F
authors.lastname: Rossetti
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000209:etiology; D006648:Histocompatibility / Q000276:immunology; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000401:mortality / Q000628:therapy*; D007962:Leukocytes; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D015999:Multivariate Analysis; D012008:Recurrence; D012074:Remission Induction; D012307:Risk Factors; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
chemical_list: D016572:Cyclosporine; D002066:Busulfan; D008727:Methotrexate